Often, when confronted with outsourcing and looking for laboratories for your discovery projects, turnaround times and cost are two very important factors. Quality and reliability of data generated are of course essential as well. How do you ensure that your expectations are fulfilled? You do that by doing a little digging – in other words, you have to ask some very simple (but probing) questions.
The first question that you ask should be about the business model and the specific strategy for the discovery project. The next question needs to be about infrastructure and depth of experience. Does the CRO have processes in place that allows it to expand rapidly when you do? In case of a significant backlog, how does the CRO you are considering prioritize? Is it a first in, first out? Or is it based on the size of your contract? Both of these approaches run the chance of having your project stuck behind another large project and/or seeing your small contract not making it to the top of the priority list.
In this webinar, you will discover the best way to identify whether the CRO you are reviewing has the capabilities to serve your full suite of discovery needs. You will learn about the specific questions to ask and the characteristics to seek out when determining the CRO best suited for the entire scope of your drug discovery project.
Sohrab Habibi Goudarzi, PhD, Senior Director, Pharmaceutical Discovery Services, KCAS Bioanalytical and Biomarker Services
Dr. Sohrab Habibi Goudarzi joined KCAS in May of 2018 as the Director of Discovery, Bioanalytical Research. He earned his PhD from Purdue University and conducted postdoctoral research at Oak Ridge National Laboratories and Cornell University. This was followed by 22 years of experience in mass spectrometry-based research and development that included instrumentation, automation, fundamentals of MS/MS and analytical and bioanalytical applications. His extensive experience has spanned both industry and academia, with 24 peer-reviewed publications and authorship of successfully funded internal and external research proposals. He was a major contributor to a NSF proposal and the principal investigator of a NIH grant.Message Presenter
John Perkins, Senior Scientific Advisor, KCAS Bioanalytical and Biomarker Services
John R. Perkins is the Senior Scientific Advisor, who has a focus on LC/MS technologies, at KCAS. Previously, he was at Q2 Solutions and The Legacy Companies for over 24 years working in quantitative LC/MS, principally with small molecules. His primary focus was on validation and sample analysis processes as well as managing customer relationships in Ithaca NY. More recently, he was responsible for the bioanalytical lab in Oss, The Netherlands.
John received his PhD in Supercritical Fluid Chromatography/Mass Spectrometry from the University of Wales, College of Cardiff, UK. He did postdoctoral research on nanoscale separation techniques with mass spectrometry at the NIEHS in the Research Triangle Park in the US. He earned his Bachelors degree in Chemistry from the University of Reading, UK and a Masters degree in Advanced Analytical Chemistry from the University of Bristol, UK.Message Presenter
Who Should Attend?
- Applicable for both pharma and biopharma individuals
What You Will Learn
- Business Model and Strategy
- Infrastructure Commitment
- Depth of experience and staff development
- Prioritization process
With over four decades of providing bioanalytical services to pharma and biotech industries, KCAS knows we have the leadership, business model, strategy, depth of experience, staff development plan, capacity forecast system, proactive resource acquisition, and the prioritization processes that makes us a viable partner for your discovery needs.